USA - NYSE:RVTY - US7140461093 - Common Stock
The current stock price of RVTY is 98.89 USD. In the past month the price increased by 17.64%. In the past year, price decreased by -14.99%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.56 | 216.18B | ||
| DHR | DANAHER CORP | 28.92 | 159.69B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 148.65 | 48.49B | ||
| A | AGILENT TECHNOLOGIES INC | 27.16 | 41.97B | ||
| IQV | IQVIA HOLDINGS INC | 19.23 | 37.49B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.07 | 29.55B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 42.07 | 21.39B | ||
| WAT | WATERS CORP | 29.39 | 21.40B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.32 | 17.00B | ||
| ILMN | ILLUMINA INC | 24.06 | 15.39B | ||
| TEM | TEMPUS AI INC | N/A | 15.50B | ||
| ICLR | ICON PLC | 13.5 | 13.85B |
Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. The company is headquartered in Waltham, Massachusetts and currently employs 11,000 full-time employees. The firm has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
REVVITY INC
77 4Th Avenue
Waltham MASSACHUSETTS US
Employees: 11000
Phone: 17816636900
Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. The company is headquartered in Waltham, Massachusetts and currently employs 11,000 full-time employees. The firm has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
The current stock price of RVTY is 98.89 USD. The price increased by 1.35% in the last trading session.
REVVITY INC (RVTY) has a dividend yield of 0.3%. The yearly dividend amount is currently 0.28.
RVTY has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
REVVITY INC (RVTY) operates in the Health Care sector and the Life Sciences Tools & Services industry.
The Revenue of REVVITY INC (RVTY) is expected to grow by 3.49% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
REVVITY INC (RVTY) has a market capitalization of 11.48B USD. This makes RVTY a Large Cap stock.
ChartMill assigns a technical rating of 6 / 10 to RVTY. When comparing the yearly performance of all stocks, RVTY is a bad performer in the overall market: 81.03% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to RVTY. RVTY has an excellent profitability rating, but there are some minor concerns on its financial health.
Over the last trailing twelve months RVTY reported a non-GAAP Earnings per Share(EPS) of 4.89. The EPS increased by 5.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.19% | ||
| ROA | 2.31% | ||
| ROE | 3.77% | ||
| Debt/Equity | 0.43 |
26 analysts have analysed RVTY and the average price target is 121.75 USD. This implies a price increase of 23.12% is expected in the next year compared to the current price of 98.89.
For the next year, analysts expect an EPS growth of 1.21% and a revenue growth 3.49% for RVTY